Lipopolysaccharides accelerate hepatic steatosis in the development of nonalcoholic fatty liver disease in Zucker rats

Journal of Clinical Biochemistry and Nutrition

Volumn 54, Issue 1, 2014, Pages 39-44

  Fukunishi, Shinya ^a   Sujishi, Tetsuya ^a   Takeshita, Atsushi ^a   Ohama, Hideko ^a   Tsuchimoto, Yusuke ^a   Asai, Akira ^a   Tsuda, Yasuhiro ^a   Higuchi, Kazuhide ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Adiponectin; Disaccharide; Hepatic steatosis; Lipopolysaccharides (LPS); Nonalcoholic fatty liver disease (NAFLD)

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; DISACCHARIDE; FAS ANTIGEN; FAT DROPLET; FATTY ACID; GLUCOSE; INSULIN; LEPTIN; LIPOPOLYSACCHARIDE; MESSENGER RNA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BODY WEIGHT; CARBOHYDRATE DIET; CONTROLLED STUDY; FATTY ACID BLOOD LEVEL; FATTY LIVER; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; KUPFFER CELL; LIPID STORAGE; LIVER FIBROSIS; LIVER INJURY; LIVER WEIGHT; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; TRIACYLGLYCEROL BLOOD LEVEL; ZUCKER RAT;

EID: 84891760764     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.13-49     Document Type: Article

References (33)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231.
2. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 1649-1657.
3. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923.
4. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003; 37: 1202-1219.
5. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1705-1725.
6. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-845.
7. Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut 2002; 50: 585-588.
8. Brun P, Castagliuolo I, Di Leo V, et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2007; 292: G518-G525.
9. Farhadi A, Gundlapalli S, Shaikh M, et al. Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int 2008; 28: 1026-1033.
10. Fukunishi S, Nishio H, Fukuda A, et al. Development of fibrosis in nonalcoholic steatohepatitis through combination of a synthetic diet rich in disaccharide and low-dose lipopolysaccharides in the livers of Zucker (fa/fa) rats. J Clin Biochem Nutr 2009; 45: 322-328.
11. Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37: 343-350.
12. Solga SF, Diehl AM. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol 2003; 38: 681-687.
13. Bergheim I, Weber S, Vos M, et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol 2008; 48: 983-992.
14. Novikoff PM. Fatty liver induced in Zucker "fatty" (ff) rats by a semisynthetic diet rich in sucrose. Pro Natl Acad Sci U S A 1977; 74: 3550-3554.
15. Halleux CM, Takahashi M, Delporte ML, et al. Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun 2001; 288: 1102-1107.
16. Kamada Y, Tamura S, Kiso S, et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003; 125: 1796-1807.
17. Caro JF, Sinha MK, Kolaczynski JW, Zhang PL, Considine RV. Leptin: the tale of an obesity gene. Diabetes 1996; 45: 1455-1462.
18. Patel K, Muir A, McHutchison JG, Patton HM. A link between leptin and steatosis in chronic hepatitis C? Time to weigh up the fats. Am J Gastroenterol 2003; 98: 952-955.
19. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
20. Holst O, Ulmer AJ, Brade H, Flad HD, Rietschel ET. Biochemistry and cell biology of bacterial endotoxin. FEMS Immunol Med Microbiol 1996; 16: 83-104.
21. Lien E, Means TK, Heine H, et al. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest 2000; 105: 497-504.
22. Uesugi T, Froh M, Arteel GE, Bradford BU, Thurman RG. Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. Hepatology 2001; 34: 101-108.
23. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 2008; 118: 829-838.
24. Srere PA. The citrate cleavage enzyme. I. Distribution and purification. J Biol Chem 1959; 234: 2544-2547.
25. Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996; 1302: 93-109.
26. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-1131.
27. Shimomura I, Bashmakov Y, Horton JD. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem 1999; 274: 30028-30032.
28. Matusoka M, Tsukamoto H. Stimulation of hepatic lipocyte collagen production by Kupffer cell-derived transforming growth factor β: implication for a pathogenic role in alcoholic liver fibrogenesis. Hepatology 1990; 11: 599-605.
29. Friedman SL. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanism and treatment strategies. N Engl J Med 1993; 328: 1828-1835.
30. Endo M, Masaki T, Seike M, Yoshimatsu H. TNF-α induces hepatic steatosis in mice by enhancing gene expression of sterol regulatory element binding protein-1c (SREBP-1c). Exp Biol Med (Maywood) 2007; 232: 614-621.
31. Paracchini V, Pedotti P, Taioli E. Genetics of leptin and obesity: a HuGE review. Am J Epidemiol 2005; 162: 101-114.
32. Imajo K, Fujita K, Yoneda M, et al. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metab 2012; 16: 44-54.
33. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52: 1836-1846.